In this week’s Eblast we have some very exciting new postings.
First is the updated HCV Drug Pipeline that has information on TMC 436, a HCV protease inhibitor (in combination with pegylated interferon plus ribavirin) that showed fantastic interim results in a phase II study.
It will be interesting to see if the final results of this study show the same trend. Of course, the study is too small to give us all the information we need but hopefully this positive data will help to push the triple combo forward into phase III study.
Another noteworthy item we posted was an Action Alert to get people to contact their representative to support an increase of up to $50 million for viral hepatitis prevention. Make yourself heard and hopefully we can get more funding for viral hepartitis.
We also have our News Review that was posted on Saturday as well as many HCSP Guides have been reviewed and updated to reflect the newest information about our understanding of various topics.
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.